Ken Griffin Taysha Gene Therapies, Inc. Put Options Transaction History

Citadel Advisors LLC

6 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q1 2024 May 15, 2024	BUY	$1.43 - $3.25 $9,724 - $22,100	6,800 Added 485.71%	8,200 $23,000
Q4 2023 Feb 14, 2024	SELL	$1.33 - $2.88 $41,629 - $90,144	-31,300 Reduced 95.72%	1,400 $2,000
Q3 2023 Nov 14, 2023	BUY	$0.63 - $3.66 $19,908 - $115,656	31,600 Added 2872.73%	32,700 $103,000
Q2 2023 Aug 14, 2023	SELL	$0.59 - $0.87 $59 - $87	-100 Reduced 8.33%	1,100 $0
Q1 2023 May 15, 2023	SELL	$0.65 - $2.3 $12,675 - $44,850	-19,500 Reduced 94.2%	1,200 $0

Q4 2022 Feb 14, 2023	BUY	$1.89 - $2.44 $39,123 - $50,508	20,700 New	20,700 $46,000

111

109M

108K

158K

Ticker TSHA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 48,359,500
Market Cap $104M
Description
Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for th...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.